CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Revenue	$ 47,397	$ 69,423	$ 94,247	$ 133,602
Operating expenses:
Cost of revenue	39,629	38,582	78,754	76,917
Selling, general and administrative	38,575	40,556	78,139	81,441
Research and development	4,882	4,924	9,770	9,956
Change in estimated fair value of contingent consideration	140	(1,195)	140	(1,195)
Goodwill impairment	30,449	0	42,884	0
Restructuring	0	(4)	0	(1,216)
Total operating expenses	113,675	82,863	209,687	165,903
Loss from operations	(66,278)	(13,440)	(115,440)	(32,301)
Other income (expense):
Interest expense	(6,815)	(11,939)	(13,593)	(22,803)
Interest income	3,030	7,086	6,255	14,296
Other expense	(4,062)	(2,562)	(4,038)	(2,456)
Loss before income taxes	(74,125)	(20,855)	(126,816)	(43,264)
Income tax benefit	(4,288)	(2,435)	(4,126)	(2,164)
Net loss	(69,837)	(18,420)	(122,690)	(41,100)
Net loss attributable to non-controlling interests	(30,246)	(8,631)	(53,154)	(19,233)
Net loss attributable to Maravai LifeSciences Holdings, Inc.	$ (39,591)	$ (9,789)	$ (69,536)	$ (21,867)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., basic (in usd per share)	$ (0.27)	$ (0.07)	$ (0.48)	$ (0.16)
Net loss per Class A common share attributable to Maravai LifeSciences Holdings, Inc., diluted (in usd per share)	$ (0.27)	$ (0.07)	$ (0.48)	$ (0.16)
Weighted average number of Class A common shares outstanding, basic (in shares)	144,236	135,842	143,833	134,088
Weighted average number of Class A common shares outstanding, diluted (in shares)	144,236	135,842	143,833	134,088